Anaplastic Thyroid Cancer - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Anaplastic Thyroid Cancer

The Experts below are selected from a list of 3528 Experts worldwide ranked by ideXlab platform

Cristina Grange – 1st expert on this subject based on the ideXlab platform

  • Combining doxorubicin-nanobubbles and shockwaves for Anaplastic Thyroid Cancer treatment: preclinical study in a xenograft mouse model
    Endocrine-related Cancer, 2017
    Co-Authors: Francesca Marano, Cristina Grange, Roberto Frairia, Letizia Rinella, Monica Argenziano, Benedetta Bussolati, Raffaella Mastrocola, Isabella Castellano, Laura Berta, Roberta Cavalli

    Abstract:

    Anaplastic Thyroid Cancer is one of the most lethal diseases, and a curative therapy does not exist. Doxorubicin, the only drug approved for Anaplastic Thyroid Cancer treatment, has a very low response rate and causes numerous side effects among which cardiotoxicity is the most prominent. Thus, doxorubicin delivery to the tumor site could be an import goal aimed to improve the drug efficacy and to reduce its systemic side effects. We recently reported that, in human Anaplastic Thyroid Cancer cell lines, combining doxorubicin-loaded nanobubbles with extracorporeal shock waves, acoustic waves used in lithotripsy and orthopedics without side effects, increased the intracellular drug content and in vitro cytotoxicity. In the present study, we tested the efficacy of this treatment on a human Anaplastic Thyroid Cancer xenograft mouse model. After 21 days, the combined treatment determined the greatest drug accumulation in tumors with consequent reduction of tumor volume and weight, and an extension of the tumor doubling time. Mechanistically, the treatment induced tumor apoptosis and decreased cell proliferation. Finally, although doxorubicin caused the increase of fibrosis markers and oxidative stress in animal hearts, loading doxorubicin into nanobubbles avoided these effects preventing heart damage. The improvement of doxorubicin anti-tumor effects together with the prevention of heart damage suggests that the combination of doxorubicin-loaded nanobubbles with extracorporeal shock waves might be a promising drug delivery system for Anaplastic Thyroid Cancer treatment.

  • histone deacetylase inhibition modulates e cadherin expression and suppresses migration and invasion of Anaplastic Thyroid Cancer cells
    The Journal of Clinical Endocrinology and Metabolism, 2012
    Co-Authors: Maria Graziella Catalano, Nicoletta Fortunati, Mariateresa Pugliese, Francesca Marano, Loredana Ortoleva, Roberta Poli, Sofia Asioli, Andrea Bandino, Nicola Palestini, Cristina Grange

    Abstract:

    Context: Anaplastic Thyroid Cancer cells are characterized by a mesenchymal phenotype, as revealed by spindle-shaped cells and absent or reduced levels of E-cadherin. Epigenetic silencing is considered one of the leading mechanisms of E-cadherin impairment, which causes the acquisition of the invasive and metastatic phenotype of Anaplastic Thyroid Cancer. Objectives: In this study we investigated the effects of histone deacetylase inhibition on E-cadherin expression, cell motility, and invasion in Anaplastic Thyroid Cancer cell cultures. Design: Three stabilized cell lines and primary cultures of Anaplastic Thyroid Cancer were treated with various histone deacetylase inhibitors. After treatment, we evaluated histone acetylation by Western blotting and E-cadherin expression by RT-real time PCR. The proper localization of E-cadherin/β-catenin complex was assessed by immunofluorescence and Western blot. Transcription activity of β-catenin was measured by luciferase reporter gene and cyclin D1 expression. The…

  • Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of Anaplastic Thyroid Cancer cells.
    The Journal of clinical endocrinology and metabolism, 2012
    Co-Authors: Maria Graziella Catalano, Nicoletta Fortunati, Mariateresa Pugliese, Francesca Marano, Loredana Ortoleva, Roberta Poli, Sofia Asioli, Andrea Bandino, Nicola Palestini, Cristina Grange

    Abstract:

    Anaplastic Thyroid Cancer cells are characterized by a mesenchymal phenotype, as revealed by spindle-shaped cells and absent or reduced levels of E-cadherin. Epigenetic silencing is considered one of the leading mechanisms of E-cadherin impairment, which causes the acquisition of the invasive and metastatic phenotype of Anaplastic Thyroid Cancer.
    In this study we investigated the effects of histone deacetylase inhibition on E-cadherin expression, cell motility, and invasion in Anaplastic Thyroid Cancer cell cultures.
    Three stabilized cell lines and primary cultures of Anaplastic Thyroid Cancer were treated with various histone deacetylase inhibitors. After treatment, we evaluated histone acetylation by Western blotting and E-cadherin expression by RT-real time PCR. The proper localization of E-cadherin/β-catenin complex was assessed by immunofluorescence and Western blot. Transcription activity of β-catenin was measured by luciferase reporter gene and cyclin D1 expression. The effect on cell motility and invasion was studied both in vitro using scratch-wound and transwell invasion assays and in Anaplastic Thyroid carcinomas tumor xenografts in mice in vivo.
    Histone deacetylase inhibition induced the E-cadherin expression and the proper membrane localization of the E-cadherin/β-catenin complex, leading to reduced Cancer cell migration and invasion.
    We here demonstrate an additional molecular mechanism for the antiCancer effect of histone deacetylase inhibition. The antiinvasive effect in addition to the cytotoxic activity of histone deacetylase inhibitors opens up therapeutic perspectives for the Anaplastic Thyroid tumor that does not respond to conventional therapy.

Andrei Iagaru – 2nd expert on this subject based on the ideXlab platform

  • F-18 FDG PET/CT demonstration of an adrenal metastasis in a patient with Anaplastic Thyroid Cancer.
    Clinical Nuclear Medicine, 2020
    Co-Authors: Andrei Iagaru, Iain Ross Mcdougall

    Abstract:

    Abstract:An adrenal metastasis was identified on an F-18 FDG PET/CT scan in a patient with Anaplastic Thyroid Cancer. There are very few reports of Thyroid Cancer, even Anaplastic Thyroid Cancer, metastasizing to the adrenal.

  • Anaplastic Thyroid Cancer with extensive skeletal muscle metastases on 18f fdg pet ct
    Clinical Nuclear Medicine, 2018
    Co-Authors: Ilana R Yurkiewicz, Kristen N Ganjoo, Andrei Iagaru

    Abstract:

    : A 61-year-old woman with newly diagnosed Anaplastic Thyroid Cancer and known metastases to the brain, lungs, and adrenal glands complained of groin muscle pain. F-FDG PET/CT was performed to assess for extent of disease and showed extensive hypermetabolic lesions throughout the skeletal musculature concerning for metastatic disease. As this would be a very rare presentation for Anaplastic Thyroid carcinoma, a biopsy of the left gluteal muscle was conducted. Pathology demonstrated Anaplastic Thyroid carcinoma, metastatic to skeletal muscle.

Jan H M Schellens – 3rd expert on this subject based on the ideXlab platform

  • dabrafenib and trametinib treatment in patients with locally advanced or metastatic braf v600 mutant Anaplastic Thyroid Cancer
    Journal of Clinical Oncology, 2018
    Co-Authors: Vivek Subbiah, Maria E. Cabanillas, Robert J Kreitman, Zev A Wainberg, Jan H M Schellens, Jeancharles Soria, Christoph C Zielinski, Gladys Urbanowitz, Bijoyesh Mookerjee

    Abstract:

    PurposeWe report the efficacy and safety of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) combination therapy in BRAF V600E–mutated Anaplastic Thyroid Cancer, a rare, aggressive, and highly lethal malignancy with poor patient outcomes and no systemic therapies with clinical benefit.MethodsIn this phase II, open-label trial, patients with predefined BRAF V600E–mutated malignancies received dabrafenib 150 mg twice daily and trametinib 2 mg once daily until unacceptable toxicity, disease progression, or death. The primary end point was investigator-assessed overall response rate. Secondary end points included duration of response, progression-free survival, overall survival, and safety.ResultsSixteen patients with BRAF V600E–mutated Anaplastic Thyroid Cancer were evaluable (median follow-up, 47 weeks; range, 4 to 120 weeks). All patients had received prior radiation treatment and/or surgery, and six had received prior systemic therapy. The confirmed overall response rate was 69% (11 of 16; 95% C…

  • Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600–mutant Anaplastic Thyroid Cancer
    Journal of Clinical Oncology, 2017
    Co-Authors: Vivek Subbiah, Maria E. Cabanillas, Robert J Kreitman, Zev A Wainberg, Jan H M Schellens, Jeancharles Soria, Christoph C Zielinski, Gladys Urbanowitz

    Abstract:

    PurposeWe report the efficacy and safety of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) combination therapy in BRAF V600E–mutated Anaplastic Thyroid Cancer, a rare, aggressive, and highly lethal malignancy with poor patient outcomes and no systemic therapies with clinical benefit.MethodsIn this phase II, open-label trial, patients with predefined BRAF V600E–mutated malignancies received dabrafenib 150 mg twice daily and trametinib 2 mg once daily until unacceptable toxicity, disease progression, or death. The primary end point was investigator-assessed overall response rate. Secondary end points included duration of response, progression-free survival, overall survival, and safety.ResultsSixteen patients with BRAF V600E–mutated Anaplastic Thyroid Cancer were evaluable (median follow-up, 47 weeks; range, 4 to 120 weeks). All patients had received prior radiation treatment and/or surgery, and six had received prior systemic therapy. The confirmed overall response rate was 69% (11 of 16; 95% C…